TOKYO , March 18, 2020  - Gifu University (President: Hisataka Moriwaki M.D., Ph.D.) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the parties have established, inside Gifu University Graduate School of Medicine, a joint research course entitled, “Phage Biologics Research Course” (Lead professor: Hiroki Nagai, Ph.D., Professor of Microbiology, Gifu University Graduate School of Medicine; Lead researcher: Hiroki Ando, Ph.D., Principal Investigator*1 of Astellas is on loan to Gifu University as project associate professor). In the Phage Biologics Research Course, Gifu University and Astellas will conduct a joint study on bacterial infection treatment by using engineered bacteriophages*2. The course will be retained for a term of  three years from March 2020.

Phage therapy is known for being a treatment that aims to selectively eliminate bacteria from the living body by using bactericidal actions, the primary properties of a virus, and taking advantage of the characteristic of viruses in the natural world that specifically infect target bacteria. Due to the advancement of genetic engineering technology, progress is being made in recent years in the research of enhancing the usefullness and safety of engineered bacteriophage. It is attracting attention as the next-generation phage therapy technology. This technology is expected to be useful not only for the treatment of common bacterial infections, but also for the new treatment of difficult-to-treat bacterial infections and for solving the problem of antimicrobial resistance  (AMR) *3, a serious global threat to public health.

Gifu University Graduate School of Medicine has been engaged for some time in the research of engineered bacteriophages applicable to next-generation phage therapy. Through this joint research, while making use of the strength of academia in which knowledge gained from clinical practice can be inputted, Gifu University will work to create engineered bacteriophages against multiple target bacteria through an industry-academia collaboration with Astellas.

The VISION of Astellas is “On the forefront of healthcare change, turning innovative science into value for patients.” Along with in-house R&D, collaborations and partnerships play an important role in realizing this VISION. Astellas actively explores and evaluates collaboration opportunities that match the company’s innovations and business strategies. The establishing of this joint research course is part of this effort.

Through this joint research, Gifu University and Astellas will take on the challenge of creating multiple lead programs in the field of bacterial infection treatment that uses engineered bacteriophages, to further bring benefit to patients.


Click below for a copy of the full press release

Contact the Media Relations team
Communications & Investor Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)